DOCSLIB.ORG

Norm Norm-Vet 2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Norm Norm-Vet 2016 Erratum NORM/NORM-VET report 2016 Unfortunately, there is a few errors in the NORM-VET 2016 report. x Page 69, paragraph on cephalosporin resistant Escherichia coli from cheese and seafood. One cephalosporin resistant E. coli was detected from a domestic seafood sample, not imported as stated in the text page 69, and in sammendrag and summary pages 8 and 12; x Table 11, page 56 in the printed NORM-VET 2016 with regard to MIC distributions for ampicillin and ceftazidime. Correct Table is as followed: TABLE 11. Antimicrobial resistance in isolates of Escherichia coli from faecal swab samples from red fox and wild birds (n=434 and n=303, respectively) in 2016. Distribution (%) of MIC values (mg/L)* Resistance (%) Substance Sample [95% CI] 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 ≥ 512 Tetracycline Fox 2.8 [1.4-4.8] 96.1 1.2 1.6 1.2 Bird 3.6 [1.8-6.4] 92.7 3.6 0.3 1.7 1.7 Tigecycline Fox 0.2 [0.0-1.3] 97.5 2.3 0.2 Bird 0.3 [0.0-1.8] 92.4 7.3 0.3 Chloramphenicol Fox 0.5 [0.1-1.7] 98.8 0.7 0.5 Bird 0.7 [0.1-2.4] 99.3 0.7 Ampicillin Fox 3.7 [2.1-5.9] 0.9 32.9 56.5 6.0 0.2 0.2 3.2 Bird 3.6 [1.8-6.4] 3.0 34.3 55.8 3.3 0.7 0.3 2.6 Cefotaxime Fox 0.0 [0.0-0.8] 100 Bird 0.0 [0.0-1.2] 100 Ceftazidime Fox 0.0 [0.0-0.8] 0.2 99.8 Bird 0.0 [0.0-1.2 100 Meropenem Fox 0.0 [0.0-0.8] 100 Bird 0.0 [0.0-1.2] 100 Sulfamethoxazole Fox 3.7 [2.1-5.9] 94.7 1.4 0.2 3.7 Bird 2.6 [1.1-5.1] 94.6 2.6 0.3 0.3 2.3 Trimethoprim Fox 1.4 [0.5-3.0] 92.2 6.0 0.5 1.4 Bird 2.3 [0.9-4.7] 84.5 12.9 0.3 2.3 Azithromycin Fox ND ND 57.1 35.0 7.6 0.2 Bird ND ND 33.7 54.5 10.6 0.7 0.3 0.3 Gentamicin Fox 0.5 [0.1-1.7] 68.0 27.6 3.9 0.5 Bird 0.0 [0.0-1.2] 88.8 9.6 1.7 Ciprofloxacin Fox 1.2 [0.4-2.7] 90.6 7.8 0.5 0.9 0.2 Bird 2.3 [0.9-4.7] 88.4 9.2 1.0 0.3 0.3 0.7 Nalidixic acid Fox 1.4 [0.5-3.0] 97.5 1.2 0.2 0.5 0.7 Bird 2.0 [0.7-4.2] 97.4 0.7 0.3 1.7 Colistin Fox 0.5 [0.1-1.7] 0.5 98.6 0.5 0.2 0.2 Bird 0.3 [0.0-1.8] 99.3 0.3 0.3 *Bold vertical lines denote epidemiological cut-off values for resistance. ND=cut-off not defined by EUCAST. CI=confidence interval. White fields denote range of dilutions tested for each antimicrobial agent. MIC values higher than the highest concentration tested are given as the lowest MIC value above the range. MIC values equal to or lower than the lowest concentration tested are given as the lowest concentration tested. 1250 12509(7 8VDJHRI$QWLPLFURELDO $JHQWVDQG2FFXUUHQFHRI $QWLPLFURELDO5HVLVWDQFH LQ1RUZD\ ,661 SULQW HOHFWURQLF $Q\XVHRIGDWDIURP125012509(7VKRXOGLQFOXGHVSHFLILFUHIHUHQFHWRWKLVUHSRUW 6XJJHVWHGFLWDWLRQ125012509(78VDJHRI$QWLPLFURELDO$JHQWVDQG2FFXUUHQFHRI$QWLPLFURELDO 5HVLVWDQFHLQ1RUZD\7URPV¡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¡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¡UQ7RUH/XQHVWDG %DFWHULDIURPELYDOYHPROOXVFV EMRUQWRUHOXQHVWDG#QLIHVQR 1,)(6 0RKDPPHG8PDHU1DVHHU (QWHURSDWKRJHQLFEDFWHULDLQKXPDQV PRKDPPHGXPDHUQDVHHU#IKLQR 1RUZ,QVWRI3XE+HDOWK 0DULRQ1HWHODQG $QWLELRWLFXVDJHLQKXPDQV PDULRQLUHQQHWHODQG#VDYQR .$6+DXNHODQG8QLY+RVS 0DGHODLQH1RUVWU|P %DFWHULDIURPDQLPDOV PDGHODLQHQRUVWURP#YHWLQVWQR 1RUZ9HW,QVW .DULQ5¡QQLQJ 7XEHUFXORVLV NDULQURQQLQJ#IKLQR 1RUZ,QVWRI3XE+HDOWK *XQQDU6NRY6LPRQVHQ %DFWHULDIURPKXPDQV JXQQDUVNRYVLPRQVHQ#XQQQR 12508QLY+RVS1RUWK1RUZ -DQQLFH6FKDX6OHWWHPHnV %DFWHULDIURPDQLPDOV MDQQLFHVFKDXVOHWWHPHDV#YHWLQVWQR 1RUZ9HW,QVW &HFLOLH6YDQHYLN %DFWHULDIURPELYDOYHPROOXVFV FHFLOLHVYDQHYLN#QLIHVQR 1,)(6 'DJILQQ6NDDUH +DHPRSKLOXVLQIOXHQ]DH GDJILQQVNDDUH#VLYQR 9HVWIROG+RVSLWDO7¡QVEHUJ 0DUWLQ6WHLQEDNN %DFWHULDIURPKXPDQV PDUWLQVWHLQEDNN#IKLQR 1RUZ,QVWRI3XE+HDOWK $QQH0DUJUHWH8UGDKO %DFWHULDIURPDQLPDOV DQQHPDUJUHWHXUGDKO#YHWLQVWQR 12509(71RUZ9HW,QVW 'LGULN9HVWUKHLP 3QHXPRFRFFL GLGULNIULPDQQYHVWUKHLP#IKLQR 1RUZ,QVWRI3XE+HDOWK ,QVWLWXWLRQVSDUWLFLSDWLQJLQ12509(7 1DWLRQDO,QVWLWXWHRI1XWULWLRQDQG6HDIRRG5HVHDUFK %M¡UQ7RUH/XQHVWDG&HFLOLH6YDQHYLN 1RUZHJLDQ)RRG6DIHW\$XWKRULW\.MHUVWL1LOVHQ%DUNEX.MHOO+DXJH6ROIULGcPGDO 1RUZHJLDQ9HWHULQDU\,QVWLWXWH $LQD6WHLKDXJ%DUVWDG$JDWKH9LNUH'DQLHOVHQ.DUL*UDYH.DUL2OOL +HOJHVHQ*UR-RKDQQHVVHQ.QXW0DGVOLHQ6ROYHLJ6¡OYHU¡G0R 0DGHODLQH1RUVWU|P-DQQLFH6FKDX6OHWWHPHnV$QQH0DUJUHWH8UGDKO ,QVWLWXWLRQVSDUWLFLSDWLQJLQ1250 $NHUVKXV8QLYHUVLW\+RVSLWDO/¡UHQVNRJ'HSDUWPHQWRI0LFURELRORJ\ %M¡UQ2GG-RKQVHQ0DULW9DWW¡\ )UVW0HGLVLQVN/DERUDWRULXP 7URQG(JLO5DQKHLP1LQD%HDWH-RKDQVHQ )¡UGH+RVSLWDO'HSDUWPHQWRI0LFURELRORJ\ 5HLGDU+MHWODQG$VWULG9HGGH +DXJHVXQG+RVSLWDO'HSDUWPHQWRI0LFURELRORJ\ /LY-RUXQQ6¡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¡GDO 1RUZHJLDQ,QVWLWXWHRI3XEOLF+HDOWK5HI/DEIRU0WXEHUFXORVLV $QQH7RUXQQ0HQJVKRHO$QQLND5HLFKPDQ 1RUZHJLDQ,QVWLWXWHRI3XEOLF+HDOWK5HI/DEIRU1JRQRUUKRHDH 0DUWLQ6WHLQEDNN*LQD,ODXJ*XOGDKO 1RUZHJLDQ,QVWLWXWHRI3XEOLF+HDOWK5HI/DEIRU1PHQLQJLWLGLV 'RPLQLTXH&DXJDQW/HQH+DDNHQVHQ 1RUZHJLDQ,QVWLWXWHRI3XEOLF+HDOWK5HI/DEIRU6SQHXPRQLDH 'LGULN9HVWUKHLP$QQH5DPVWDG$OPH 1RUZHJLDQ,QVWLWXWHRI3XEOLF+HDOWK5HI/DEIRU6S\RJHQHV 0DUWLQ6WHLQEDNN$QQH5DPVWDG$OPH 1RUGODQG+RVSLWDO%RG¡'HSDUWPHQWRI0LFURELRORJ\ 6DQGUDcVKHLP7RQMH+RODQ 2VOR8QLYHUVLW\+RVSLWDO5DGLXPKRVSLWDOHW/DERUDWRU\RI0LFURELRORJ\ *RUP+DQVHQ6XQQLYD)DJHUnV5¡VW 2VOR8QLYHUVLW\+RVSLWDO5LNVKRVSLWDOHW,QVWLWXWHRI0HGLFDO0LFURELRORJ\ *RUP+DQVHQ%HOLQGD/DQJQHV/LQGVWDG 2VOR8QLYHUVLW\+RVSLWDO5LNVKRVSLWDOHW5HI/DEIRU0\FRORJ\ &HFLOLH7RUS$QGHUVHQ/RQQ\0DUJUHWKH.O¡YIMHOO 2VOR8QLYHUVLW\+RVSLWDO8OOHYnO'HSDUWPHQWRI0LFURELRORJ\ *DXWH6\YHUVHQ7KHD%HUJKHLP 6WDYDQJHU8QLYHUVLW\+RVSLWDO'HSDUWPHQWRI0LFURELRORJ\ 0RQLFD5HJLQH5RPVWDG$QLWD/¡YnV%UHNNHQ 6W2ODY8QLYHUVLW\+RVSLWDO7URQGKHLP'HSDUWPHQWRI0LFURELRORJ\ .MHUVWL:LN/DUVVHQ$OH[DQGHU+XVE\5LFKDUGVHQ 6W2ODY8QLYHUVLW\+RVSLWDO7URQGKHLP5HI/DE IRU056$ .MHUVWL:LN/DUVVHQ$UVDODQ0RJKHQ 6W2ODY8QLYHUVLW\+RVSLWDO7URQGKHLP5HI/DEIRU6DJDODFWLDH $OHNVDQGUD-DNRYOMHY5DQGL9DOV¡/\QJ 6¡UODQGHW+RVSLWDO.ULVWLDQVDQG'HSDUWPHQWRI0LFURELRORJ\ 6WnOH7RIWHODQG/LVH+XOO¡HQ2U¡ 8QLODEV7HOHODE$66NLHQ .ULV]WLQD3DSS$QQH5DJQKLOG2VHLG 8QLYHUVLW\+RVSLWDORI1RUWK1RUZD\7URPV¡'HSDUWPHQWRI0LFURELRORJ\ *XQQDU6NRY6LPRQVHQ%ULDQ*XHQQLJVPDQ 8QLYHUVLW\+RVSLWDORI1RUWK1RUZD\1DW$GY8QLWRQ'HWHFWLRQRI$05 UMDQ6DPXHOVHQ%M¡UJ&+DOGRUVHQ 9HVWIROG+RVSLWDO7¡QVEHUJ'HSDUWPHQWRI0LFURELRORJ\ 'DJILQQ6NDDUH$VWULG/LD 9HVWUH9LNHQ% UXP+RVSLWDO'HSDUWPHQWRI0HGLFDO0LFURELRORJ\ $QQHWWH2QNHQ0HUULDP6XQGEHUJ 9HVWUH9LNHQ'UDPPHQ+RVSLWDO'HSDUWPHQWRI0HGLFDO0LFURELRORJ\ (LQDU7ROODNVHQ:HPH+DQQH)DQXHOVHQ VWIROG+RVSLWDO)UHGULNVWDG'HSDUWPHQWRI0LFURELRORJ\ 6DUD'HEHV$QQH&DWKULQH+ROOHNLP cOHVXQG+RVSLWDO'HSDUWPHQWRI0LFURELRORJ\ (LQDU1LOVHQ/XLVD-RKDQVHQ 1250UHIHUHQFHJURXSLQ 0DUWLQ6WHLQEDNN 1RUZ,QVW3XE+HDOWK 'DJ+DUDOG6NXWODEHUJ +DXNHODQG8QLY+RVS +HLGL&HFLOLH9LOOPRQHV 9HVWIROG+RVS7UXVW $DVPXQG)RVWHUYROG 1RUZ6RF0HG0LFURELRO 7KHD%HUJKHLP 1RUZ6RF(QJLQHHUVDQG7HFKQRORJLVWV -RQ%LUJHU+DXJ 1RUZ6RF,QI'LV .QXW(LULN(OLDVVHQ 1RUZ&ROO*HQ3UDFW 125012509(7 ,1752'8&7,21 &217(176 ,QWURGXFWLRQ««««««««««««««««««««««««««««««««« 6DPPHQGUDJ«««««««««««««««««««««««««««««« 6XPPDU\«««««««««««««««««««««««««««««««««« 3RSXODWLRQVWDWLVWLFV««««««««««««««««««««««««««««««« 8VDJHRIDQWLPLFURELDODJHQWV 8VDJHLQDQLPDOV 7KHUDSHXWLFXVDJHRIYHWHULQDU\DQWLPLFURELDODJHQWV«««««««««««««««« $QWLPLFURELDODQGFRFFLGLRVWDWIHHGDGGLWLYHV««««««««««««««««« 8VDJHLQKXPDQV 2YHUDOODQWLELRWLFVDOHV««««««««««««««««««««««««««« $QWLELRWLFXVDJHLQSULPDU\FDUH«««««««««««««««««««««««« $QWLELRWLFXVDJHLQKRVSLWDOFDUH««««««««««««««««««««««« 1DWLRQDO$FWLRQ3ODQDJDLQVW$QWLELRWLF5HVLVWDQFHLQ+HDOWKFDUH«««««««««« $QWLP\FRWLFXVDJHLQ1RUZD\«««««««««««««««««««««««« 2FFXUUHQFHRIDQWLPLFURELDOUHVLVWDQFH ,QGLFDWRUEDFWHULDIURPDQLPDOV 3URGXFWLRQDQLPDOV««««««««««««««««««««««««««««« :LOGDQLPDOV«««««««««««« ,QGLFDWRUEDFWHULDIURPIRRG««««««««««««««««««««««««« ,QGLFDWRUEDFWHULDIURPIHHG««««««««««««««««««««««««««« =RRQRWLFDQGQRQ]RRQRWLFHQWHURSDWKRJHQLFEDFWHULD
Load more

Recommended publications
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • Antibiotic Use in Pregnancy and Lactation What Is and Is Not Known About Teratogenic and Toxic Risks
    Reviews Antibiotic Use in Pregnancy and Lactation What Is and Is Not Known About Teratogenic and Toxic Risks Gerard G. Nahum, MD, CAPT Kathleen Uhl, USPHS, and CAPT Dianne L. Kennedy, USPHS OBJECTIVE: Over ten million women are either pregnant icol, ciprofloxacin, doxycycline, levofloxacin, and or lactating in the United States at any time. The risks of rifampin) to “undetermined” (clindamycin, gentamicin, medication use for these women are unique. In addition and vancomycin). Assessments were based on “good to normal physiologic changes that alter the pharmaco- data” (penicillin G and VK), “fair data” (amoxicillin, chlor- kinetics of drugs, there is the concern of possible terato- amphenicol, ciprofloxacin, doxycycline, levofloxacin, and genic and toxic effects on the developing fetus and rifampin), “limited data” (clindamycin and gentamicin), newborn. This article reviews the risks and pharmacoki- and “very limited data” (vancomycin). Significant phar- netic considerations for 11 broad-spectrum antibiotics macokinetic changes occurred during pregnancy for the that can be used to treat routine and life-threatening penicillins, fluoroquinolones and gentamicin, indicating infections during pregnancy and lactation. that dosage adjustments for these drugs may be neces- sary. With the exception of chloramphenicol, all of these DATA SOURCES: Information from the U.S. Food and antibiotics are considered compatible with breastfeed- Drug Administration (FDA) product labels, the Teratogen ing. Information Service, REPROTOX, Shepard’s Catalog of Teratogenic Agents, Clinical Pharmacology, and the peer- CONCLUSION: Health care professionals should con- reviewed medical literature was reviewed concerning the sider the teratogenic and toxic risk profiles of antibiotics use of 11 antibiotics in pregnant and lactating women.
    [Show full text]
  • Acinetobacter Baumannii Resistance: a Real Challenge for Clinicians
    antibiotics Review Acinetobacter baumannii Resistance: A Real Challenge for Clinicians Rosalino Vázquez-López 1,* , Sandra Georgina Solano-Gálvez 2, Juan José Juárez Vignon-Whaley 1 , Jorge Andrés Abello Vaamonde 1 , Luis Andrés Padró Alonzo 1, Andrés Rivera Reséndiz 1, Mauricio Muleiro Álvarez 1, Eunice Nabil Vega López 3, Giorgio Franyuti-Kelly 3 , Diego Abelardo Álvarez-Hernández 1 , Valentina Moncaleano Guzmán 1, Jorge Ernesto Juárez Bañuelos 1, José Marcos Felix 4, Juan Antonio González Barrios 5 and Tomás Barrientos Fortes 6 1 Departamento de Microbiología del Centro de Investigación en Ciencias de la Salud (CICSA), FCS, Universidad Anáhuac México Norte, Huixquilucan 52786, Mexico; [email protected] (J.J.J.V.-W.); [email protected] (J.A.A.V.); [email protected] (L.A.P.A.); [email protected] (A.R.R.); [email protected] (M.M.Á.); [email protected] (D.A.Á.-H.); [email protected] (V.M.G.); [email protected] (J.E.J.B.) 2 Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de Mexico 04510, Mexico; [email protected] 3 Medical IMPACT, Infectious Diseases Department, Mexico City 53900, Mexico; [email protected] (E.N.V.L.); [email protected] (G.F.-K.) 4 Coordinación Ciclos Clínicos Medicina, FCS, Universidad Anáhuac México Norte, Huixquilucan 52786, Mexico; [email protected] 5 Laboratorio de Medicina Genómica, Hospital Regional “1º de Octubre”, ISSSTE, Av. Instituto Politécnico Nacional 1669, Lindavista, Gustavo A. Madero, Ciudad de Mexico 07300, Mexico; [email protected] 6 Dirección Sistema Universitario de Salud de la Universidad Anáhuac México (SUSA), Huixquilucan 52786, Mexico; [email protected] * Correspondence: [email protected] or [email protected]; Tel.: +52-56-270210 (ext.
    [Show full text]
  • Acinetobacter Baumannii in a Murine Thigh-Infection Model
    RESEARCH ARTICLE Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model Bing Fan1,2☯, Jie Guan3☯, Xiumei Wang4, Yulong Cong1* 1 Clinical Laboratory of South Building, Chinese People’s Liberation Army General Hospital, Beijing 100853, a11111 China, 2 Clinical Laboratory of the Second Clinical District, the General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China, 3 Department of Clinical Laboratory, Peking University First Hospital, Beijing 100034, China, 4 Department of Clinical Laboratory, the General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China ☯ These authors contributed equally to this work. * [email protected] OPEN ACCESS Citation: Fan B, Guan J, Wang X, Cong Y (2016) Abstract Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Few effective therapeutic options are available for treating severe infections caused by Sulbactam against Extensively Drug-Resistant extensively drug-resistant Acinetobacter baumannii (XDR-AB). Using a murine thigh-infec- Acinetobacter baumannii in a Murine Thigh-Infection tion model, we examined the in vivo efficacy of colistin in combination with meropenem, tige- Model. PLoS ONE 11(6): e0157757. doi:10.1371/ journal.pone.0157757 cycline, fosfomycin, fusidic acid, rifampin, or sulbactam against 12 XDR-AB strains. Colistin, tigecycline, rifampin, and sulbactam monotherapy significantly decreased bacterial Editor: Digby F. Warner, University of Cape Town, SOUTH AFRICA counts in murine thigh infections compared with those observed in control mice receiving no treatment. Colistin was the most effective agent tested, displaying bactericidal activity Received: February 13, 2016 against 91.7% of strains at 48 h post-treatment.
    [Show full text]
  • Antimicrobials: Leaky Barrier Boosts Antibiotic Action
    RESEARCH HIGHLIGHTS Nature Reviews Microbiology | AOP, published online 26 November 2012; doi:10.1038/nrmicro2931 ANTIMICROBIALS Leaky barrier boosts antibiotic action The nascent polypeptide exit tun‑ Even after exposure to 100‑fold the the drug), the chimeric protein by- nel (NPET), which accommodates minimum inhibitory concentration passed erythro­mycin. This ability was the newly synthesized proteins as they of erythromycin, protein production preserved when several synonymous physiochemical make their way out of the bacterial continued at ~6% of the normal codon substitutions were introduced properties of ribosome, is the target of macrolide level, and strikingly, telithromycin in the hns segment, showing that it is antibiotics. It was generally assumed treatment permitted protein synthe­ the amino acid sequence of the nas‑ the N terminus that these drugs inhibit bacterial sis at ~25% of the normal level. cent peptide, rather than the mRNA determine growth by causing a global arrest in Two-dimensional gel electrophoresis sequence, that accounts for drug whether a protein synthesis; however, a new revealed that many of the synthesized evasion. Furthermore, the protein protein can study now reveals that macrolides proteins were drug specific, indicat‑ HspQ, which contains an N terminus permit translation of a distinct subset ing that the chemical structure of the resembling that of H‑NS, was also circumvent of proteins, and that this could be macrolide determined the spectrum capable of by-passing erythromycin. the macrolide even more detrimental to the cell. of proteins synthesized. Together, these data suggest that the barrier. Macrolides bind to a narrow So what features of the protein physiochemical properties of the region of the NPET and were previ‑ define its ability to by-pass the drug? N terminus determine whether a ously believed to block the passage Mass spectrometry of the synthesized protein can circumvent the macrolide of all proteins.
    [Show full text]
  • Ketek, INN-Telithromycin
    authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICSlonger no product Medicinal 1 1. NAME OF THE MEDICINAL PRODUCT Ketek 400 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 400 mg of telithromycin. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Light orange, oblong, biconvex tablet, imprinted with ‘H3647’ on one side and ‘400’ on the other. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications authorised When prescribing Ketek, consideration should be given to official guidance on the appropriate use of antibacterial agents and the local prevalence of resistance (see also sections 4.4 and 5.1). Ketek is indicated for the treatment of the following infections: longer In patients of 18 years and older: • Community-acquired pneumonia, mild or moderate (see section 4.4). • When treating infections caused by knownno or suspected beta-lactam and/or macrolide resistant strains (according to history of patients or national and/or regional resistance data) covered by the antibacterial spectrum of telithromycin (see sections 4.4 and 5.1): - Acute exacerbation of chronic bronchitis, - Acute sinusitis In patients of 12 years and older: • Tonsillitis/pharyngitis caused by Streptococcus pyogenes, as an alternative when beta lactam antibiotics are not appropriateproduct in countries/regions with a significant prevalence of macrolide resistant S. pyogenes, when mediated by ermTR or mefA (see sections 4.4 and 5.1). 4.2 Posology and method of administration Posology The recommended dose is 800 mg once a day i.e. two 400 mg tablets once a day. In patients of 18 years and older, according to the indication, the treatment regimen will be: - Community-acquired pneumonia: 800 mg once a day for 7 to 10 days, Medicinal- Acute exacerbation of chronic bronchitis: 800 mg once a day for 5 days, - Acute sinusitis: 800 mg once a day for 5 days, - Tonsillitis/pharyngitis caused by Streptococcus pyogenes: 800 mg once a day for 5 days.
    [Show full text]
  • Linezolid - Tigecycline
    Linezolid - Tigecycline Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology Louvain Drug Research Institute Catholic University of Louvain, Brussels, Belgium With the support of Wallonie-Bruxelles-International 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 1 Dong-A pharmaceuticals and tedizolid: step #1 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 2 Mode of action: • Protein synthesis inhibition: LZD binds to the 23S portion of the ribosomal 50S subunit (the centre of peptidyl transferase activity) → no initial complex 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 3 RNA interaction Karen L. Leach et al, Molecular Cell (2007) 26,393-402 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 4 Spectrum of activity No useful activity against other Gram-negative organisms because of constitutive efflux ! 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 5 Registered clinical indications Linezolid is often used off-label (endocarditis, osteomyelitis, ….) in pace of vancomycin 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 6 Linzezolid: mechanism of resistance 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 7 Can linzolid induce resistance ? 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 8 Linzolid can induce resistance… Locke et al. Antimicrob Agent Chemother 2009;53:5265-5274. 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 9 Linezolid pharmacokinetics 12-11-2015 WBI - HUP Cooperation - Bach Mai Hospital 10 Linezolid human pharmacokinetics Oral therapeutic doses (600mg linezolid q12h for 21 days) Linezolid Tedizolid MIC 90 MIC90 Muñoz et al. ECCMID 2010; P1594 Flanagan SD, et al. Pharmacotherapy 2014;34(3):240–250.
    [Show full text]
  • Stability of Neomycinresistance in Staphylococcus Aureus
    J. clin. Path., 1970, 23, 19-23 Stability of neomycin resistance in J Clin Pathol: first published as 10.1136/jcp.23.1.19 on 1 February 1970. Downloaded from Staphylococcus aureus G. A. J. AYLIFFE From the Hospital Infection Research Laboratory, Summerfield Hospital, Birmingham SYNOPSIS A strain of Staphylococcus aureus isolated from the skin of a subject with eczema showed a loss in resistance to neomycin and tetracycline after treatment with neomycin was stopped. Seven out of 22 strains of neomycin-resistant Staph. aureus showed a loss in resistance to neomycin and streptomycin after storage in nutrient broth for 14 days at room temperature, and it seems probable that resistance in these unstable strains was controlled by extra- chromosomal elements or plasmids. Strains of phage types 84/85 and 29/77 and related types were frequently isolated in general hospital wards and showed no loss in resistance on similarcopyright. storage in nutrient broth. Five of the neomycin-unstable strains were isolated frompatientswith eczematous lesions. Multiple-resistant and antibiotic-sensitive strains ofStaph.aureus of similar phage type were isolated from patients in a ward for patients with skin disease, and the pos- sibility oftransfer ofresistance in vivo is discussed. http://jcp.bmj.com/ The selection of neomycin-resistant strains of In the present study, changes in resistance to on September 30, 2021 by guest. Protected Staph. aureus by neomycin or related compounds antibiotics of Staph. aureus isolated from the and the disappearance after discontinuing the eczematous subject after discontinuing treatment use of these antibiotics has been shown in a with neomycin were investigated.
    [Show full text]
  • Antibiotic Resistance in Plant-Pathogenic Bacteria
    PY56CH08-Sundin ARI 23 May 2018 12:16 Annual Review of Phytopathology Antibiotic Resistance in Plant-Pathogenic Bacteria George W. Sundin1 and Nian Wang2 1Department of Plant, Soil, and Microbial Sciences, Michigan State University, East Lansing, Michigan 48824, USA; email: [email protected] 2Citrus Research and Education Center, Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Lake Alfred, Florida 33850, USA Annu. Rev. Phytopathol. 2018. 56:8.1–8.20 Keywords The Annual Review of Phytopathology is online at kasugamycin, oxytetracycline, streptomycin, resistome phyto.annualreviews.org https://doi.org/10.1146/annurev-phyto-080417- Abstract 045946 Antibiotics have been used for the management of relatively few bacterial Copyright c 2018 by Annual Reviews. plant diseases and are largely restricted to high-value fruit crops because of Access provided by INSEAD on 06/01/18. For personal use only. All rights reserved the expense involved. Antibiotic resistance in plant-pathogenic bacteria has Annu. Rev. Phytopathol. 2018.56. Downloaded from www.annualreviews.org become a problem in pathosystems where these antibiotics have been used for many years. Where the genetic basis for resistance has been examined, antibiotic resistance in plant pathogens has most often evolved through the acquisition of a resistance determinant via horizontal gene transfer. For ex- ample, the strAB streptomycin-resistance genes occur in Erwinia amylovora, Pseudomonas syringae,andXanthomonas campestris, and these genes have pre- sumably been acquired from nonpathogenic epiphytic bacteria colocated on plant hosts under antibiotic selection. We currently lack knowledge of the effect of the microbiome of commensal organisms on the potential of plant pathogens to evolve antibiotic resistance.
    [Show full text]
  • Informatorium of COVID-19 Drugs in Indonesia" Has Been Compiled and Can Be Published Amidst the COVID-19 Outbreak in Indonesia
    THE INDONESIAN FOOD AND DRUG AUTHORITY INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY MARCH 2020 1 INFORMATORIUM OF COVID-19 DRUGS IN INDONESIA THE INDONESIAN FOOD AND DRUG AUTHORITY ISBN 978-602-415-009-9 First Edition March 2020 COPYRIGHT PROTECTED BY LAW Reproduction of this book in part or whole, in any form and by any means, mechanically or electronically, including photocopies, records, and others without written permission from the publisher. This informatorium is based on information up to the time of publication and is subject to change if there is the latest data/information 2 3 FOREWORD Our praise and gratitude for the presence of God Almighty for His blessings and gifts, "The Informatorium of COVID-19 Drugs in Indonesia" has been compiled and can be published amidst the COVID-19 outbreak in Indonesia. As we know, the infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) began to plague in December 2019 in Wuhan City, Hubei Province, People's Republic of China. The disease was caused by SARS-CoV-2 infection which was later known as Coronavirus Disease 2019 (COVID-19) which in early 2020 began to spread to several countries and eventually spread to almost all countries in the world. On March 11, 2020, WHO announced COVID-19 as a global pandemic. In Indonesia, the first case was officially announced on March 2, 2020. Considering that the spread of COVID-19 has been widespread and has an impact on social, economic, defense, and public welfare aspects in Indonesia, the President of the Republic of Indonesia established the Task Force for the Acceleration of COVID- 19 Handling aiming to increase readiness and ability to prevent, detect and respond to COVID-19.
    [Show full text]
  • A Genome-Wide Screen in Saccharomyces Cerevisiae Reveals a Critical Role for the Mitochondria in the Toxicity of a Trichothecene Mycotoxin
    A genome-wide screen in Saccharomyces cerevisiae reveals a critical role for the mitochondria in the toxicity of a trichothecene mycotoxin John E. McLaughlina,1, Mohamed Anwar Bin-Umera,1, Andrew Tortoraa, Natasha Mendeza, Susan McCormickb, and Nilgun E. Tumera,2 aBiotechnology Center for Agriculture and the Environment and the Department of Plant Biology and Pathology, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ, 08901-8520; and bMycotoxin Research Unit, National Center for Agricultural Utilization Research, United States Department of Agriculture, Agricultural Research Service, Peoria, IL, 61604 Edited by Joan Wennstrom Bennett, Rutgers University, New Brunswick, NJ; and approved October 19, 2009 (received for review August 27, 2009) Trichothecene mycotoxins synthesized by Fusarium species are transferase center in Saccharomyces cerevisiae and inhibit potent inhibitors of eukaryotic translation. They are encountered peptidyltransferase activity of eukaryotic ribosomes (7–9). in both the environment and in food, posing a threat to human and Trichodermin-resistant yeast mutants were also resistant to animal health. They have diverse roles in the cell that are not anisomycin (9) and the trichodermin binding site on the 60S limited to the inhibition of protein synthesis. To understand the ribosomal subunit was closely related to the binding site of trichothecene mechanism of action, we screened the yeast knock- anisomycin (9, 10). out library to identify genes whose deletion confers resistance to Trichothecenes and translation inhibitors like anisomycin that trichothecin (Tcin). The largest group of resistant strains affected target the peptidyltransferase center are known to induce the mitochondrial function, suggesting a role for fully active mitochon- ribotoxic stress response that leads to rapid activation of mitogen dria in trichothecene toxicity.
    [Show full text]